Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4643]

ESMO 2017: Abemaciclib initial therapy improves outcome in endocrine-sensitive advanced breast cancer

ESMO 2017: Abemaciclib initial therapy improves outcome in endocrine-sensitive advanced breast cancer

ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer

ESMO 2017: Ramucirumab plus docetaxel improves progression-free survival in urothelial cancer

ESMO 2017: Cancer patients struggle with key aspects of clinical trials

ESMO 2017: Cancer patients struggle with key aspects of clinical trials

ESMO 2017: Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer

ESMO 2017: Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer

ESMO 2017: Durvalumab improves progression-free survival in stage III lung cancer

ESMO 2017: Durvalumab improves progression-free survival in stage III lung cancer

European Alliance for Personalised Medicine discusses historic FDA approval for CAR T-cell therapy

European Alliance for Personalised Medicine discusses historic FDA approval for CAR T-cell therapy

ESMO 2017: Taselisib boosts breast tumour shrinkage in LORELEI trial

ESMO 2017: Taselisib boosts breast tumour shrinkage in LORELEI trial

ESMO 2017: Promising response rate to pembrolizumab in pretreated metastatic gastric cancer

ESMO 2017: Promising response rate to pembrolizumab in pretreated metastatic gastric cancer

ESMO 2017: New data confirms superiority of docetaxel based triplet therapy in gastric cancer

ESMO 2017: New data confirms superiority of docetaxel based triplet therapy in gastric cancer

ESMO 2017: DNA sequencing could open up new drug indications for patients with rare cancers

ESMO 2017: DNA sequencing could open up new drug indications for patients with rare cancers

More from ecancer